In a filing, Mind Medicine Inc revealed its Chief Executive Officer Barrow Robert unloaded Company’s shares for reported $0.14 million on Mar 25 ’25. In the deal valued at $6.74 per share,21,208 shares were sold. As a result of this transaction, Barrow Robert now holds 856,556 shares worth roughly $6.12 million.
Then, Karlin Daniel sold 6,836 shares, generating $46,075 in total proceeds. Upon selling the shares at $6.74, the Chief Medical Officer now owns 446,177 shares.
Before that, Sullivan Mark sold 6,576 shares. Mind Medicine Inc shares valued at $44,322 were divested by the Chief Legal Officer at a price of $6.74 per share. As a result of the transaction, Sullivan Mark now holds 316,621 shares, worth roughly $2.26 million.
Evercore ISI initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on January 28, 2025; the price target was $23. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. ROTH MKM started covering the stock on July 24, 2024. It rated MNMD as “a Buy”.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock fall -0.42% to $7.14. Over the last five days, the stock has lost -7.99%. Mind Medicine Inc shares have risen nearly 2.59% since the year began. Nevertheless, the stocks have fallen -9.04% over the past one year. While a 52-week high of $10.44 was reached on 02/14/25, a 52-week low of $4.70 was recorded on 04/09/25.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 7.05, which if violated will result in even more drops to 6.96. On the upside, there is a resistance level at 7.26. A further resistance level may holdings at 7.38.
The most recent change occurred on May 29, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $27 price target.
